what is known already: A bolus of hCG for final maturation of follicles in connection with COS may induce the risk of OHSS and the luteal phase progesterone levels rise very abruptly in the early luteal phase. study design, size, duration: This is a proof-of-concept study conducted as a three arm RCT with a total of 93 patients. First patient enrolled in January 2012 and the study finished in January 2014.
Introduction
Shortly after the introduction of the long GnRH agonist (GnRHa) protocol in the late 1980s it was realized that luteal phase support in the form of exogenous progesterone increased ongoing pregnancy rates after ovarian stimulation for IVF (Edwards et al., 1980; Smitz et al., 1992) . Controlled ovarian stimulation (COS) with exogenous stimulation with gonadotrophins, resulted in multiple corpora lutea (CL) and supraphysiological luteal steroid levels, which prevented sufficient secretion of endogenous LH via pituitary negative feed-back mechanisms (Tavaniotou et al., 2001; Fauser and Devroey, 2003; Tavaniotou and Devroey, 2003) . The luteal LH deficiency was only overcome once the implanting embryo started to secrete hCG .
As early luteal LH is mandatory for the function of CL as well as the up-regulation of growth factors and cytokines involved in implantation, the un-supplemented luteal phase resulted in implantation failure and early pregnancy loss (Beckers et al., 2003; Humaidan et al., 2012) . Although the hCG trigger bolus used for final oocyte maturation compensated for the initial pituitary LH insufficiency, the majority of patients benefitted from exogenous progesterone supplementation and it became mandatory to provide luteal phase support for all COS cycles.
The importance of the mid-luteal progesterone level for implantation and ongoing pregnancy was further highlighted with the introduction of the GnRH antagonist protocol and GnRHa trigger for final oocyte maturation. The first randomized controlled studies on GnRHa trigger reported very low mid-luteal phase progesterone levels despite a standard luteal phase support consisting of vaginal progesterone and oral estradiol. This resulted in high early pregnancy loss rates and unacceptably low birth rates (Humaidan et al., 2005) . Subsequent studies showed that pregnancy rates similar to those of hCG trigger could be obtained after GnRHa trigger, provided that a small bolus of 1.500 IU hCG was administered on the day of oocyte retrieval to compensate for the LH deficiency induced by the COS and GnRHa trigger. Thus, it was shown that the 1.500 IU bolus of hCG augmented mid-luteal phase progesterone levels and normalized the early pregnancy loss rate (Humaidan et al., 2006 (Humaidan et al., , 2010 (Humaidan et al., , 2013 Humaidan, 2009; Humaidan and Alsbjerg, 2014; Yding Andersen and Vilbour Andersen, 2014) . Further, the GnRHa trigger concept combined with the administration of 1.500 IU hCG proved to significantly reduce the OHSS incidence, mainly due to the fact that the mid-cycle surge of gonadotrophins elicited by GnRHa has a considerably shorter duration as compared with hCG trigger and with the natural mid-cycle surge of gonadotrophins (Hoff et al., 1983; Damewood et al., 1989; Gonen et al., 1990; Itskovitz et al., 1991) .
The GnRHa trigger concept has released a new intriguing possibility of using a combined collective effect of hCG for follicular stimulation in the follicular phase (Filicori et al., 2002 (Filicori et al., , 2005 Blockeel et al., 2009 ) combined with final maturation of follicles with GnRHa trigger and for luteal phase support. The present study explores this option and has used low-dose hCG for COS during the follicular phase. The remaining hCG from the follicular phase acted in combination with the GnRHa trigger in synergy to induce final maturation of oocytes. The action of hCG was continued during the luteal phase by using the remaining hCG present in circulation plus low-dose hCG as the only luteal phase support (Kol et al., 2011) . Thus this concept with only endogenous progesterone production may improve patient convenience by avoiding either leaky vaginal progesterone administration or painful i.m. injections.
The present proof-of-concept study explored the combined use of low-dose daily rhCG during the follicular and luteal phases of IVF/ICSI patients who were triggered with GnRHa and who did not receive any other luteal phase support. The control group received a standard antagonist protocol with rhCG trigger and standard luteal phase support.
Materials and Methods
In this three arm proof-of-concept study a total of 93 IVF patients were randomized. All patients were enrolled at The Fertility Clinic, Skive Regional Hospital, Denmark. The inclusion criteria were: (i) female age between 25 and 40 years, (ii) baseline FSH and LH , 12 IU/l, (iii) menstrual cycle length between 25 and 34 days, (iv) body mass index (BMI) between 18 and 30, (v) both ovaries present and absence of any uterine abnormalities. The exclusion criteria were: (i) PCOS according to the Rotterdam criteria, or a total antral follicle count ≥24, (ii) hypothalamic dysfunction, (iii) diabetes, epilepsy, liver, renal, heart disease or other metabolic disorders.
This study was approved by the local Ethics Committee of Region Midt. Written informed consent was obtained from each of the patients enrolled.
Hormonal treatment
A schematic presentation of the stimulation protocols used in the study is shown in Fig. 1 .
Control group
From cycle day 2 -5 a fixed dose of rFSH 150 -225 IU (Gonal-F, MerckSerono, Hellerup, Denmark) was administered daily depending on age, BMI, basal FSH, antral follicle count and the ovarian volume. After 4 days dose adjustment was allowed depending on the ovarian response. GnRH antagonist co-treatment 0.25 mg s.c. daily (Cetrotide, Merck-Serono, Hellerup, Denmark) started on the fifth day of stimulation and was administered until and including the day of inducing final follicular maturation. As soon as three follicles reached ≥17 mm, ovulation was induced by the administration of a single bolus of 250 mg rhCG (Ovitrelle, Merck-Serono, Hellerup, Denmark) followed by oocyte pick up (OPU) 35 h later. For luteal phase support micronized progesterone was administered vaginally, 90 mg per day (Crinone; Merck-Serono, Hellerup, Denmark) plus estradiol 4 mg per day orally (Estrofem; Novo Nordisk, Copenhagen, Denmark) commencing on the day after OPU and continuing until the day of the pregnancy test.
Study group I
From cycle day 2 -5 a fixed dose of rFSH 150 -225 IU (Gonal-F, MerckSerono, Hellerup, Denmark) was administered for 4 days, followed by adjustments in rFSH according to ovarian response. As soon as four follicles reached more than 12-13 mm, rFSH was discontinued while stimulation with 200 IU rhCG was started on a daily basis. GnRH antagonist co-treatment 0.25 mg s.c. daily (Cetrotide, Merck-Serono, Hellerup, Denmark) started on the fifth day of stimulation. As soon as three follicles reached ≥17 mm, final follicular maturation was induced with one bolus of 0.5 mg buserelin (Suprefact; Sanofi-Aventis, Hørsholm, Denmark). Following OPU 125 IU rhCG s.c. was administered on a daily basis for luteal phase support (See instructions for dilution below). Administration of rhCG continued until the pregnancy test was performed. No exogenous progesterone was administered.
Study group II
From cycle day 2 -5 a fixed dose of 150 -225 IU (Gonal-F, Merck-Serono, Hellerup, Denmark Gonal-F) as well as rhCG 150 IU (Ovitrelle, MerckSerono, Hellerup, Denmark) was administered for 4 days, followed by adjustments in the rFSH dose according to ovarian response. As soon as four follicles reached more than 12 -13 mm, rFSH stimulation was discontinued and the 150 IU of rhCG continued (Ovitrelle, Merck-Serono, Hellerup, Denmark)-see instructions for dilution below. GnRH antagonist co-treatment 0.25 mg s.c. daily (Cetrotide, Merck-Serono, Hellerup, Denmark) started on the fifth day of stimulation. As soon as three follicles reached ≥17 mm, induction of ovulation was performed with one bolus of 0.5 mg Buserelin (Suprefact; Sanofi-Aventis, Hørsholm, Denmark). Following OPU, 125 IU rhCG s.c. was administered on a daily basis for luteal phase support. Administration of rhCG continued until the pregnancy test was performed. No exogenous progesterone was administered.
Laboratory procedures
Laboratory procedures were similar for all patients, independent of the randomization performed. A maximum of two embryos was transferred on Day 2 or 3 after retrieval. All laboratory parameters including fertilization and cleavage rates were monitored. A biochemical pregnancy was defined by a plasma b-hCG concentration ≥20 IU/l on Day 12 after embryo transfer (ET). Clinical pregnancy was defined as an intrauterine gestational sac with a heartbeat 3 weeks after a positive hCG-test. Ongoing pregnancy was defined as an intrauterine gestational sac with a heartbeat at 10 weeks of gestation.
Randomization
Participating patients were randomized to one of three groups on stimulation day 1 (see consort diagram Fig. 2) . A study nurse performed the randomization, using computer-generated random numbers in sealed, unlabeled envelopes, each containing a unique study number. Only one cycle per patient was included. Neither doctors nor participants or nurses administering the interventions were blinded to group assignment.
Blood samples and hormone assays
Blood samples were drawn on the following days: (i) the day of ovulation induction, (ii) the day of OPU, (iii) the day of OPU plus seven and (iv) on Day 12 after embryo transfer. Serum aliquots were stored at 2208C for subsequent analysis of progesterone, estradiol and hCG. The hormones were measured in one run, using the routine assays employed by the Clinical Biochemistry Department, University Hospital of Aarhus, Denmark.
Outcome measures
The primary outcome was the mid-luteal phase serum progesterone level. Secondary outcome measures included serum hCG levels, the clinical Figure 1 Schematic representation of the stimulation protocols used for women receiving IVF treatment in a RCT of follicular phase hCG administration, GnRHa trigger and low-dose hCG for luteal phase support compared with a standard protocol.
Low-dose hCG as luteal phase support pregnancy rate, ongoing pregnancy rate, the early pregnancy loss rate and the ovarian hyperstimulation syndrome (OHSS) rate.
Dilution of rhCG for stimulation
One pen of rhCG (Ovitrelle, Merck-Serono, Hellerup, Denmark) contains 250 mg rhCG, corresponding to 6.500 IU. From a bottle containing 10 ml physiological saline, 0.5 ml was discarded and 6.500 IU rhCG in 0.5 ml solution was injected into the 9.5 ml solution, resulting in a concentration of 650 IU/ml. Using a 1 ml syringe the following doses were used during the study: 200 IU rhCG: 0.31 ml of the solution, 125 IU rhCG: 0.19 ml of the solution, 150 IU rhCG: 0.23 ml of the solution.
The rhCG for stimulation was prepared on a daily basis and pre-trial control measurements of the hCG concentration verified the amount of rhCG present in the diluted solution. 
Classification of OHSS
Classification of OHSS was performed as previously described (Humaidan et al., 2013) . In brief, moderate OHSS was defined as abdominal distension and discomfort, nausea with or without vomiting, ultrasound evidence of ascites, ovarian diameters of 8 -12 cm, hematocrit ,45% and weight gain ,2 kg.
Severe OHSS was defined as ovarian enlargement, ascites with or without hydrothorax, hematocrit .45%, weight gain .2 kg, WBC (white blood cell count) .15.000, oliguria, creatinine of 1.0 -1.5, creatinine clearance of .50 Ml/ml, liver dysfunction and edema anasarca.
Power calculation and statistics
As this was a proof-of-concept study, a power calculation was not considered applicable. For comparisons of serum hormone levels, ANOVA was used with a Student's t-test as a post hoc test. Categorical values were analyzed by use of the chi square or Fisher's exact test. A P-value .0.05 was accepted as statistically significant.
Results

Patient characteristics and stimulation
Ninety-three patients were randomized and all patients had oocyte retrieval and no patients were lost to follow-up. The three groups were comparable as regards demographic data ( Table I) .
The number of stimulation days as well as the number of IVF and ICSI cycles was similar between the three groups. The FSH consumption was reduced by around 30% in the two study groups as compared with the control group, mirrored by an hCG consumption in the two treatment groups in the same order of magnitude as the reduction in FSH consumption.
Reproductive outcome
All relevant clinical outcome parameters describing the reproductive outcomes of randomized patients entering the protocol were similar, irrespective of the type of protocol used (Table II) . Importantly, no difference was seen between the study groups who had no exogenous luteal progesterone supplementation and the control group.
Serum hormone levels
On the day of administration of either hCG (control) or GnRHa trigger (study groups) for final maturation of oocytes the mean levels of estradiol and progesterone were similar between the three groups (Table III) . The hCG levels in study group 1 and 2 were similar ( 5 IU/l) on the day of ovulation induction, despite different hCG regimes during the follicular phase. On the day of oocyte pick up hCG levels in the control group receiving 6500 IU hCG reached a mean of 74 IU/l. This contrasts the GnRHa trigger group in which the hCG administered during the follicular phase was present at a low concentration of around 2 IU/l. All groups had significantly elevated levels of progesterone as compared with preinduction of final follicular maturation; however, progesterone levels were two to three times higher in the hCG group as compared with the GnRHa trigger groups.
During the luteal phase significant differences between the control group and the study groups were observed, progesterone levels being significantly higher in the two study groups (P , 0.009) who received daily low-dose hCG supplementation. The hCG levels were on average 3.4 IU/l in group 1 and 3.2 IU/l in group 2-significantly higher than the mean hCG level (1.8 IU/l) of the control group. Moreover, estradiol levels during the mid-luteal phase were significantly higher in the two study groups as compared with the control group.
When the hormone levels in women, who achieved a positive or negative pregnancy test were calculated, only a few statistical differences were observed (Table IV) . However, hormone levels during the mid-luteal phase appeared to be higher in the group of patients who subsequently achieved a positive pregnancy test (Table V) . If the two study groups who received an identical luteal phase support (125 IU hCG daily) are combined, hCG and estradiol levels were significantly elevated in the group of patients with a positive pregnancy test (hCG: P , 0.01; estradiol: P ¼ 0.05), while the difference for progesterone did not reach statistical significance (data not shown).
OHSS
In total four moderate late onset OHSS cases were seen, two in the control group (6%) and one in each of the study groups (3%). None of the patients needed hospitalization.
Discussion
To our knowledge, this is the first proof-of-concept study performed as a small RCT to demonstrate the efficacy of an exogenous progesterone free luteal phase support in GnRHa triggered IVF/ICSI cycles in terms of not only luteal phase steroids, but also the reproductive outcome.
The administration of 125 IU hCG daily resulted in significantly higher progesterone levels during the mid-luteal phase as compared with the standard protocol in which vaginal micronized progesterone was administered on a daily basis. Moreover, the daily low-dose luteal hCG circumvented the sharp incline in the progesterone serum level and the supra-physiological steroid level traditionally seen during the early luteal phase after hCG trigger (Fauser et al., 2002) . Thus, use of the GnRHa trigger plus low-dose hCG for luteal phase support appeared to resemble more the relatively slow increase in progesterone concentration observed during the natural cycle in the early luteal phase than the hCG trigger. It is notable that the mean levels of hCG at no point exceeded the normal physiological LH level (i.e. 3-8 IU/l), demonstrating that even modest The full protocol is shown in Fig. 1 . NS, not significant.
Low-dose hCG as luteal phase support luteal hCG stimulation sufficiently supports the function of the CL after GnRHa trigger. Importantly, the reproductive outcome with the exogenous progesterone free luteal phase after GnRHa trigger was similar to that of hCG trigger and standard luteal phase support. The present low-dose hCG protocol stimulates the CL to secrete a significantly higher amount of progesterone than standard care, demonstrating that providing supra-physiological levels of hCG for luteal phase support may not be necessary. The low-dose hCG stimulation of the CL will also stimulate the production of a number of other substances believed to be of importance for early pregnancy, including other sex steroids, peptide hormones, cytokines and growth factors (Devoto et al., 2009) . Further, the proximity of the CL to the endometrium facilitates an enhanced effect on the endometrium by a first pass effect of the high concentrations of progesterone and other substances in the veins draining the ovary (Abecia et al., 1997) . Thus, in sheep the average progesterone concentration in the ovarian vein was reported to be 800-fold higher than the mean jugular venous level and samples from ovarian veins contra-lateral to CL-bearing ovaries showed an average progesterone concentration that was 30 times lower. Moreover, it was shown that the average progesterone level in the uterine vein was 30-fold higher than in the jugular vein (Abecia et al., 1997) .
The mean progesterone level achieved with our new protocol far exceeds the circulation levels of progesterone achieved by other forms of exogenous luteal phase support like intra-vaginal tablets, gel, and i.m. injections in oil.
Further, it is remarkable that mid-luteal estradiol and hCG levels were significantly higher whereas differences in progesterone levels did not reach significance in the group of patients who conceived as compared with those who did not conceive. During the mid-luteal phase, the endogenous hCG production by the implanting embryo is not yet measurable in circulation, and the difference between those who conceived and those who did not is interesting as it may point at specific endocrine effects of hCG, important for early implantation.
It has previously been shown that a period of very low circulating hCG levels exists during the mid-luteal phase after trigger with a standard bolus of 5000-10 000 IU hCG (Yding Andersen and Vilbour Andersen, 2014) just when implantation takes place and hCG from the implanting embryo has only just started to increase. In this context, it has been suggested (5.3-10. 3) (7.9-15.7) (6.8-10.8) (7.7-27.5) (9.7-24.2) Day of OPU + 7 4.6 + 0.9 4.5 + 0.6 6.4 + 0.9 4.4 + 0.5 7.5 + 1. Data are mean + SEM (range). The full protocol is shown in Fig. 1 . OI, ovulation induction; NA, not applicable NS, not significant, P . 0.05. implantation may be improved by increasing progesterone levels above a lower threshold value (Humaidan et al., 2006 (Humaidan et al., , 2010 (Humaidan et al., , 2013 Yding Andersen and Vilbour Andersen, 2014) . This study confirms and extends previous studies showing that FSH administration during the follicular phase can be replaced by hCG on a close to one to one basis, thus reducing the FSH consumption by 20-30% (Filicori et al., 2002 (Filicori et al., , 2005 Blockeel et al., 2009) . In addition, the residual hCG activity in circulation as measured on the day of induction of final oocyte maturation (≈5 IU/l hCG) will act in synergy with the GnRHa trigger to provide a 'dual' trigger that augment the area under the curve of LH activity released compared with the GnRHa trigger alone. In addition, it was suggested that the reduced number of follicles recruited and the presence of fewer small follicles, following late follicular hCG administration might reduce the risk of OHSS (Filicori et al., 2002 (Filicori et al., , 2005 .
As previously shown, the survival and functioning of the newly formed CL are dependent upon stimulation with LH-like activity, which in our currently employed GnRHa trigger protocol is done by administering a bolus of 1500 IU hCG on the day of OPU (Humaidan et al., 2006 (Humaidan et al., , 2010 (Humaidan et al., , 2013 Humaidan, 2009 ). This bolus of hCG, however, does not seem to be necessary using the present concept, in which the remaining hCG activity-left over from the follicular phase-in addition to the 125 IU hCG daily, starting from the day of OPU will cover the luteal phase support. Thereby, the present concept avoids a peak concentration of hCG of around 35 -50 IU/l during the early luteal phase which is the result of the administration of 1500 IU hCG (Humaidan et al., 2006 (Humaidan et al., , 2010 (Humaidan et al., , 2013 .
The study was too small to reveal significant differences regarding the reproductive outcome. Interestingly, the use of low-dose hCG from Day 1 of stimulation does not seem to provide additional benefit as compared with Day 6 that fits with the low level of LH receptor expression on human granulosa cells from human antral follicles with a diameter of 4-10 mm with only larger follicles being responsive to LH (Jeppesen et al., 2012) .
Although the daily low hCG injection as performed in the present study has not been developed for routine clinical use yet, and it might be considered cumbersome with daily dilutions performed by the patient herself after meticulous instruction by nurses, the majority of patients were very satisfied to avoid luteal leaky daily vaginal progesterone administration or painful i.m. injections. We envision that a future drug with a steady long-acting low dose LH-like activity release, covering the entire or part of the luteal phase with only physiological LH-like concentrations could be attractive from both an efficacy, safety, and a convenience standpoint to a large number of patients.
It is acknowledged that the present study resulted in a total of four moderate late onset OHSS cases, of which two occurred in the control group and one in each of the study groups. This shows that even with low physiological levels of hCG, late onset OHSS may not be completely eliminated after GnRHa trigger.
Taken together, this study explored the combined effects of rhCG supplementation to rFSH stimulation during either the early-or late follicular phase of IVF/ICSI cycles, followed by GnRHa trigger and daily low-dose luteal rhCG supplementation. As the luteal rhCG supplementation boosted the endogenous progesterone production during the luteal phase, no additional exogenous luteal progesterone supplementation was needed. The results of this proof-of concept study warrant further investigation and a larger RCT is planned to substantiate the efficacy of the novel concept.
